Hos patienter med pulmonal arteriel hypertension kan der være en potential øget risiko for blødning, når sildenafil initieres hos patienter, der allerede anvender en vitamin- K- antagonist, især hos patienter med pulmonal arteriel hypertension sekundært til bindevævssygdom.
In pulmonary arterial hypertension patients, there may be a potential for increased risk of bleeding when sildenafil is initiated in patients already using a Vitamin K antagonist, particularly in patients with pulmonary arterial hypertension secondary to connective tissue disease.